SAL0140
/ Shenzhen Salubris
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 18, 2026
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
(clinicaltrials.gov)
- P2 | N=252 | Recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P2 trial • Cardiovascular • Hypertension
June 16, 2026
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease
(clinicaltrials.gov)
- P2 | N=249 | Not yet recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P2 trial • Chronic Kidney Disease • Nephrology • Renal Disease
June 12, 2026
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P2 trial • Endocrine Disorders
July 07, 2025
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
(clinicaltrials.gov)
- P1 | N=82 | Recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
New P1 trial • Cardiovascular • Hypertension
1 to 4
Of
4
Go to page
1